In addition, gene expression and pathway analyses from Affymetrix microarrays of locally advanced or metastatic ER+ tumours in the TransConfirm trial uncovered unique ER-mediated gene signatures that conferred decreased response to fulvestrant [82]. Here, ESR1 is linked to neoplasm.